Frederik E. Deiman
Groningen, GR 9713GZ, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progression.
Journal: Cardiovascular research
Published: January 14, 2026
Immune cell signature in non-ischemic heart failure indicates chronic systemic immune activation with features of immunosenescence.
Journal: Immunity & ageing : I & A
Published: January 05, 2026
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy.
Journal: Signal transduction and targeted therapy
Published: December 15, 2025
RNA Therapeutics in Heart Failure.
Journal: Journal of cardiovascular translational research
Published: January 31, 2025
Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort.
Journal: Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
Published: January 28, 2025
IL-17 is associated with disease severity and targetable inflammatory processes in heart failure.
Journal: ESC heart failure
Published: June 20, 2024
Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del.
Journal: Current heart failure reports
Published: May 19, 2022
Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes.
Journal: International journal of molecular sciences
Published: September 28, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026